"[Eli Lilly & Co.] plans to disclose payments to doctors." (Associated Press, 9/24/08)

"Top-Selling Prescription Drug Mismarketed to Women." (Blackwell Publishing, 9/17/08)

"Drug companies spend billions each year peddling pills to consumers. Does it work? A new study says no." (Forbes.com, 9/1/08)

"Stanford to Limit Drug Maker Financing." (New York Times, 8/25/08)

"Don't become a victim of medical marketing." (CNN.com, 8/21/08)

"Move Over, Couch: Psych Pills Take Over; In Era of Pills, Fewer Shrinks Doing Talk Therapy." (ABC News, 8/4/08)

"Wyeth Reports New Subpoenas in Protonix Investigation." (Bloomberg.com, 8/4/08)

"AstraZeneca defends drug's soaring sales: Lawsuits claim Seroquel marketed to doctors illegally." (The News Journal (Delaware), 8/3/08)

"Legislature votes to crack down on companies' gifts to doctors." (Boston Globe, 7/31/08)

"Lilly Trained Sales Force to Ignore Drug's Risks." (Bloomberg.com, 7/31/08)

"Grassley, Dingell Lead Calls For Overhauling FDA." (Wall Street Journal, 7/30/08)

"The Evidence Gap: A series." NY Times series that explores medical treatments used despite a lack of a rigorous evidence base. (New York Times, 7/29/08)

"FDA faulted over unapproved uses of medications." (Associated Press, 7/27/08)

"In Industry CME, $85,000 buys you 90 minutes, $103,000 buys one article." (Carlat Psychiatry Blog, 7/18/08)

"It's Not the Answers That Are Biased, It's the Questions." (Washington Post, 7/15/08)

"Psychiatric Group Faces Scrutiny Over Drug Industry Ties." (New York Times, 7/12/08)

"PhRMA’s New Code: Secret Documents Revealed." (Carlat Psychiatry Blog, 7/11/08)

"Drug marketing code draws line at gift pens." (Reuters, 7/10/08)

"8-Year-Olds on Statins? A New Plan Quickly Bites Back." (New York Times, 7/8/08)

"Costly Cancer Drug Offers Hope, but Also a Dilemma." (New York Times, 7/6/08)

"Pfizer To End Direct Support For Commercial Doctor Courses." (CNNMoney.com, 7/2/08)

"Weighing the Costs of a CT Scan’s Look Inside the Heart." (New York Times, 6/29/08)

"Implant firms pay doctors millions: As joint replacements have increased, so have payments to surgeons." (Philadelphia Inquirer, 6/29/08)

"Drug Companies Paying Doctors?" Video discusses the money physicians receive from drug companies for fees and services. (CBS News, 6/26/08)

"Senate Targets Stanford Psychiatrist Over Conflicts" (Pharmalot (Blog), 6/25/08)

"Doctors Say Medication Is Overused in Dementia." (New York Times, 6/24/08)

"Americans want to know about pharma freebies, poll finds." (Boston Globe, 6/18/08)

"3 doctors facing conflict of interest investigation." (Boston Globe, 6/10/08)

Survey of medical schools by AMSA is critical of perks. (New York Times, 6/3/08)

Bill in California would allow pharmacies to sell their medical records to pharmaceutical companies, allowing them to created individualized adds targeted at specific patients. (San Francisco Chronicle, 5/28/08)

"Without TV ads, restless legs may take a hike." The approval of generic drugs for the condition will most likely lead to less marketing and, with it, decreased prevalence of a disease experts say was overhyped by drug company promotion. (MSNBC, 5/14/08)

"Drugmakers need to rein in ads, hearing told." (Reuters, 5/8/08)

"Ortho-Evra Patch Exposes Women to Dangerous Estrogen Levels, Risk of Blood Clots, Public Citizen Tells FDA." (Public Citizen, 5/8/08)

"Association of American Medical Colleges proposes ban on 'pharma' gifts to physicians, staff, medical students." (New York Times, 4/28/08)

"Maker of Vioxx is accused of deception." Two original research articles in JAMA, along with an editorial, effectively "accuse one of the world's biggest pharmaceutical makers of various forms of scientific fraud." (Washington Post, 4/16/08)

"The real benefit of some cancer drugs may be exaggerated because of a growing tendency for firms and investigators to call a premature halt to trials the moment a benefit appears." (Guardian, 4/9/08)

"American Medical Student Association Partners With Pharmedout.Org To Offer Guide On Hosting Industry-Free Meetings." (Medical News Today, 4/8/08)

"Tainted medicine: Financial conflicts of interest are raising some upsetting questions about the trustworthiness of research." (LA Times, 4/6/08)

Cardiologists say two widely prescribed cholesterol-lowering drugs, Zetia (ezetimibe) and Vytorin (combination of ezetimibe and simvastatin), may not work and should be used only as a last resort. (New York TImes, 3/31/08)

“Generic drugs are just as good.” An Op-Ed that addresses some of the misinformation represented in the previous LA Times article on the topic. (LA Times, 3/27/08)

Patients who receive free drug samples from their doctors end up having significantly higher out-of-pocket costs for their prescription drugs than people who don't receive free samples, a new study finds. (Washington Post, 3/24/08)

A federal investigation into the orthopedic device industry’s suspected kickback payments to hip and knee surgeons has intensified scrutiny of physicians. (New York Times, 3/22/08)

“Countering the Drug Salesman,” an editorial in favor of having government-funded health professionals visit doctors to provide unbiased guidance about medications in an effort to counter the one-sided sales pitches from pharm reps. (New York Times, 3/20/08)

“Generics: Just as good?” A disappointing article that makes assertions based on anecdotal, rather than evidence-based, information. (LA Times, 3/17/08)

"Oregon Academy of Family Physicians to Industry: Hands Off Our CME!" (Carlat Psychiatry Blog, 3/11/08)

“Lilly waited too long to warn about schizophrenia drug, doctor testifies.” (New York Times, 3/8/08)

The Association of American Medical Colleges (AAMC) and the Association of American Universities (AAU) is calling for all medical schools and major research universities to design and implement conflict of interest policies by 2010. (AAMC.org, 2/28/08)

An organization independent of pharmaceutical funding is using counter-detailers to educate physicians in Pennsylvania about which medications really work best. (The Boston Globe, 2/26/08)

British physician offers two solutions to the problem of pharmaceutical companies suppressing the release of unflattering data. (Guardian, 2/27/08)

Facing increasing public and Congressional scrutiny, Pfizer withdraws Lipitor advertising featuring Dr. Robert Jarvik. (Wall Street Journal, 2/25/08)

“Researcher: FDA Was Too Slow On Trasylol: Tells 60 Minutes He Estimates 22,000 Lives Could Have Been Saved.” (60 Minutes, 2/17/08)

The FDA may soon allow drug companies to market off-label usage of medications to physicians, a process that is currently illegal. (Wall Street Journal, 2/16/08)

“Drug Ads Raise Questions for Heart Pioneer.” Dr. Jarvik and his questionable endorsement of Lipitor is still making headlines. (New York Times, 2/7/08)

A physician tipped GlaxoSmithKline about an upcoming publication in the NEJM of safety questions involving the company’s diabetes drug Avandia. The physician has earned $75,000 in consulting and speaker fees from GSK since 1999. (New York Times, 1/30/08)

Financial ties between surgeons and the manufacturer of an artificial spinal disk are cited as issue in spine study.  (New York Times, 1/30/08)

Dr. Jarvik responds to Lipitor ad controversy in this video interview.  When asked about the lack of generics being mentioned in his spots, Jarvik responds “I don’t know. We have talked about generics in the ad.”  Uh, no you haven’t. (ABCNews.com, 1/16/08)

“Study Reveals Doubt on Drug for Cholesterol.”  Article holds Merck accountable for not publishing the essentially negative results of the Enhance trial, a study investigating the efficacy of ezetimibe (brand name Zetia, which is also included in Vytorin, a combination of ezetimibe and simvastatin) on arterial plaque formation. (New York Times, 1/15/08)

Article about Dr. Robert Jarvik, a physician advertiser for Pfizer, that makes one wonder where does his loyalty lie? With patients or with Pfizer? (Slate, 1/10/08)

House Energy & Commerce Committee announced it was probing Pfizer advertisements that feature Dr. Jarvik over concern that the commercials may mislead consumers. (Reuters, 1/7/08)

UMass Memorial Medical Center recently adopted some of the strictest conflict of interest rules in the country, sharply limiting the close ties between physicians and the makers of drugs and medical devices. (Boston Globe, 12/24/07)

“Dr. Drup Rep.”  In this New York Times Magazine article, Dr. Carlat discusses his experiences as an industry-sponsored speaker. (New York Times, 11/25/07)

“Wooing the Gatekeeper: Doctor, just a little something for you.  Complex sales strategies go way beyond freebies.” (LA Times, 8/6/07)

“Free drug samples have hidden drawbacks.” (Consumer Reports, 8/07)

“Under the influence.”  Steve Kroft of 60 Minutes reports on the pharmaceutical lobbyists influence over the Medicare prescription drug plan.  Among other interesting points, Kroft discloses that at least 15 former legislators, federal government officials, and congressional staffers who worked to pass Medicare Part D now work for large pharmaceutical companies and lobbies. Article and Video (CBS News, 7/29/07)

A website where drug and medical-device sales reps hash out their lives and work through various discussion threads. (New York Times, 6/11/07)

“Free Drug Samples? Bad idea, some say.”  (New York Times, 5/1/07)

“The doctor won't see you now.”  Big Pharma shows sign of clamping down on pharm reps over concerns of their damaged reputation. (BusinessWeek, 2/5/07)

JAMA says it was again misled. (New York Times, 7/13/06)

Financial ties to industry cloud major depression study. (Wall Street Journal, 7/11/06)

“Doctors Object to Gathering of Drug Data.”  Physicians express concern over the AMA’s sale of individual prescription data to the pharmaceutical industry.  (New York Times, 5/4/06)

“Rent-a-researcher: did a British university sell out to Procter & Gamble?”  Researcher claims that pharm company denied him access to key data and then tried to ghostwrite his analysis of it. (Slate, 12/22/05)

“Gimme an Rx! Cheerleaders Pep Up Drug Sales.” (New York Times, 11/28/05)

Senate leader Bill Frist calls for limits on drug ads. (New York Times, 7/2/05)

“Spin Doctored: How drug companies keep tabs on physicians.” (Slate, 5/31/05)

“What Can We Learn from Medical Whistleblowers? Their experiences paint a troubling picture of American medicine's ties with the pharmaceutical industry.” (PLoS Medicine, 5/27/05)